Who makes IODEX® balm?

IODEX® balm is developed by GlaxoSmithKline.

What development phase is IODEX® balm in?

IODEX® balm is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

IODEX® balm

GlaxoSmithKline · FDA-approved active Small molecule Quality 0/100

IODEX® balm, marketed by GlaxoSmithKline, holds a position in the over-the-counter topical analgesic market. The key composition patent for IODEX® balm is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk to IODEX® balm is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	IODEX® balm
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Topical Application of Iodex® Balm on Local Surface Temperature (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IODEX® balm CI brief — competitive landscape report
IODEX® balm updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI